Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options.

Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options.
复制标题

DOI:
10.1016/j.epidem.2016.10.006
复制
发表时间:
2016-12
期刊:
影响因子:
3.8
通讯作者:
Lopman, Benjamin A.
Lopman, Benjamin A.
中科院分区:
医学2区
文献类型:
--
作者:
Steele, Molly K.;Remais, Justin V.;Gambhir, Manoj;Glasser, John W.;Handel, Andreas;Parashar, Umesh D.;Lopman, Benjamin A.

文献摘要

参考文献

被引文献

相似文献

Noroviruses are the leading cause of acute gastroenteritis and foodborne diarrheal disease in the United States. Norovirus vaccine development has progressed in recent years, but critical questions remain regarding which age groups should be vaccinated to maximize population impact. We developed a deterministic, age-structured compartmental model of norovirus transmission and immunity in the U.S. population. The model was fit to age-specific monthly U.S. hospitalizations between 1996 and 2007. We simulated mass immunization of both pediatric and elderly populations assuming realistic coverages of 90% and 65%, respectively. We considered two mechanism of vaccine action, resulting in lower vaccine efficacy (lVE) between 22% and 43% and higher VE (hVE) of 50%. Pediatric vaccination was predicted to avert 33% (95% CI: 27%, 40%) and 60% (95% CI: 49%, 71%) of norovirus episodes among children under five years for lVE and hVE, respectively. Vaccinating the elderly averted 17% (95% CI: 12%, 20%) and 38% (95% CI: 34%, 42%) of cases in 65+ year olds for lVE and hVE, respectively. At a population level, pediatric vaccination was predicted to avert 18–21 times more cases and twice as many deaths per vaccinee compared to elderly vaccination. The potential benefits are likely greater for a pediatric program, both via direct protection of vaccinated children and indirect protection of unvaccinated individuals, including adults and the elderly. These findings argue for a clinical development plan that will deliver a vaccine with a safety and efficacy profile suitable for use in children.
DOI: 10.1056/nejmoa1101245
发表时间: 2011-12-08
期刊: The New England journal of medicine
影响因子: --
作者:
Atmar RL;Bernstein DI;Harro CD;Al-Ibrahim MS;Chen WH;Ferreira J;Estes MK;Graham DY;Opekun AR;Richardson C;Mendelman PM
通讯作者: Mendelman PM
DOI: 10.3201/eid1908.130465
发表时间: 2013-08
影响因子: 11.8
作者:
Hall AJ;Lopman BA;Payne DC;Patel MM;Gastañaduy PA;Vinjé J;Parashar UD
通讯作者: Parashar UD
DOI: 10.1093/cid/ciq163
发表时间: 2011-02-01
影响因子: 11.8
作者:
Lopman, Ben A.;Hall, Aron J.;Parashar, Umesh D.
通讯作者: Parashar, Umesh D.
DOI: 10.1093/aje/kwq021
发表时间: 2010-05-01
影响因子: 5
作者:
Phillips, Gemma;Tam, Clarence C.;Lopman, Ben
通讯作者: Lopman, Ben
DOI: 10.3201/eid1408.071114
发表时间: 2008-08
影响因子: 11.8
作者:
Patel, Manish M.;Widdowson, Marc-Alain;Glass, Roger I.;Akazawa, Kenichiro;Vinje, Jan;Parashar, Umesh D.
通讯作者: Parashar, Umesh D.